Brief: Milestone Pharma Progresses Clinical & Regulatory Activities For Etripamil
06/03/2023 12:53
March 6 (Reuters) - Milestone Pharmaceuticals Inc
MIST.O :
* MILESTONE PHARMACEUTICALS PROGRESSES CLINICAL AND
REGULATORY
ACTIVITIES FOR ETRIPAMIL IN PATIENTS WITH PAROXYSMAL
SUPRAVENTRICULAR TACHYCARDIA
* MILESTONE PHARMACEUTICALS INC - NODE-303 AND
RAPID-EXTENSION
STUDIES ARE COMPLETE
* MILESTONE PHARMACEUTICALS INC - FOLLOWING FDA FEEDBACK,
ETRIPAMIL NDA IS ON-TRACK FOR SUBMISSION IN Q3 OF 2023
Source text for Eikon: ID:nCNWPchc2a
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview